Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Sagimet Biosciences Capex-to-Revenue Related Terms
Sagimet Biosciences Capex-to-Revenue Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs EDIT, AUTL, FBRX: Capex-to-Revenue Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Capex-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Capex-to-Revenue falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (STU:0O2) has a Capex-to-Revenue of 0.00 as of Mar. 2026. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Capex-to-Revenue too high?
Sagimet Biosciences' current Capex-to-Revenue is 0.00. Overall, Sagimet Biosciences has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Capex-to-Revenue compare to EDIT and AUTL?
Sagimet Biosciences' Capex-to-Revenue of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Revenue for a Biotechnology company?
A good Capex-to-Revenue depends on the Biotechnology industry context. However, Capex-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Revenue mean?
A high Capex-to-Revenue can signal that a stock is expensive relative to its fundamentals. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Capex-to-Revenue is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Sagimet Biosciences (STU:0O2) is currently considered Modestly Overvalued. The stock's GF Value™ is €5.69, compared to a current price of €6.44 — trading 13.2% above its estimated fair value. The current Capex-to-Revenue is 0.00. Sagimet Biosciences' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Revenue calculated?
Capex-to-Revenue is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Capex-to-Revenue is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?
Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued.
The current stock price of €6.44 is trading 13.2% above its estimated GF Value™ of €5.69.
GuruFocus considers Sagimet Biosciences to be Modestly Overvalued.
Key valuation signals for STU:0O2:
Capex-to-Revenue: 0.00
GF Value™: €5.69 vs. price of €6.44 (13.2% above fair value)
No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
38GF Score
Get the complete analysis for STU:0O2
Capex-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
